Varian’s HyperSight Imaging OK’ed for TrueBeam & Edge Radiotherapy Systems

Varian, a Siemens Healthineers company, has gained U.S. Food and Drug Administration (FDA) 510(k) clearance for its TrueBeam and Edge radiotherapy systems that feature the HyperSight imaging solution.
 
HyperSight allows acquisition of high-quality images during a daily course of radiation treatments. The better image quality aims to target tumor volumes more precisely and spare healthy tissue during radiation treatments. Using HyperSight, linear accelerators in Varian’s portfolio can produce images that offer the Hounsfield Unit (HU) accuracy needed to plan treatment directly on acquired conebeam CT (CBCT) images.
 
The technology can be used for offline adaptive planning to account for anatomical changes to the tumor and surrounding organs over the treatment course without needing a trip to a separate CT scanner.
 
Images are acquired from HyperSight on TrueBeam and Edge for all anatomical site with 50% gantry rotation, according to Varian. Reducing CBCT acquisition time reduces motion-related artifacts due to the patient moving.
 
The Cancer Institute at Northwell Lenox Hill in New York was one of the early adopters of HyperSight imaging on their Halcyon system. “HyperSight imaging has allowed us to improve patient comfort by decreasing the time patients spend on the treatment table while simultaneously targeting with greater confidence,” said Dr. Wesley Talcott, assistant professor and radiation oncologist, department of radiation medicine at Lenox Hill Hospital. “We look forward to further streamlining care for our patients using HyperSight.”
 
HyperSight was first launched in 2022 on Varian’s Ethos and Halcyon therapy systems.
 
“As a Siemens Healthineers company, we are pioneering innovative solutions to advance radiotherapy and connect the power of imaging, both inside and outside the treatment room,” said Arthur Kaindl, head of Varian. “We are excited to expand HyperSight imaging technology to our TrueBeam and Edge platforms and further collaborate with our clinical partners to provide an integrated portfolio that connects the dots along the cancer care continuum.”